CERS1

ceramide synthase 1, the group of CERS class homeoboxes

Basic information

Region (hg38): 19:18868545-18896727

Previous symbols: [ "LASS1" ]

Links

ENSG00000223802NCBI:10715OMIM:606919HGNC:14253Uniprot:P27544AlphaFoldGenCCjaxSfariGnomADPubmedClinVar

Phenotypes

GenCC

Source: genCC

  • progressive myoclonic epilepsy type 8 (Limited), mode of inheritance: AR
  • progressive myoclonic epilepsy type 8 (Supportive), mode of inheritance: AR
  • progressive myoclonic epilepsy type 8 (Strong), mode of inheritance: AR

Clinical Genomic Database

Source: CGD

ConditionInheritanceIntervention CategoriesIntervention/Rationale Manifestation CategoriesReferences
Epilepsy, progressive myoclonic 8ARGeneralGenetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testingNeurologic19243074; 24782409

ClinVar

This is a list of variants' phenotypes submitted to ClinVar and linked to the CERS1 gene.

  • not provided (7 variants)
  • Progressive myoclonic epilepsy type 8 (1 variants)
  • Visceral heterotaxy (1 variants)

Variants pathogenicity by type

Statistics on ClinVar variants can assist in determining whether a specific variant type in the CERS1 gene is commonly pathogenic or not.

In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.

Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.

Variant type Pathogenic Likely pathogenic VUS Likely benign Benign Sum
synonymous
86
clinvar
3
clinvar
89
missense
125
clinvar
1
clinvar
126
nonsense
1
clinvar
1
clinvar
2
start loss
0
frameshift
1
clinvar
1
inframe indel
6
clinvar
6
splice donor/acceptor (+/-2bp)
1
clinvar
1
splice region
6
19
2
27
non coding
8
clinvar
16
clinvar
83
clinvar
72
clinvar
7
clinvar
186
Total 9 16 217 159 10

Highest pathogenic variant AF is 0.0000272

Variants in CERS1

This is a list of pathogenic ClinVar variants found in the CERS1 region.

You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.

Position Type Phenotype Significance ClinVar
19-18868612-C-T Likely benign (Sep 06, 2019)1078878
19-18868614-C-T not specified Uncertain significance (Oct 05, 2023)1007022
19-18868620-C-A not specified Uncertain significance (Dec 08, 2021)2262848
19-18868621-C-T Likely benign (Aug 27, 2022)1969745
19-18868623-CCAT-C Right atrial isomerism Pathogenic (Apr 18, 2018)522570
19-18868624-C-T Likely pathogenic (Apr 02, 2021)1507891
19-18868625-A-G Congenital heart defects, multiple types, 6 • Heart, malformation of Pathogenic/Likely pathogenic (Sep 08, 2023)522571
19-18868629-C-G GDF1-related disorder Uncertain significance (Jun 21, 2024)3353344
19-18868640-C-T Uncertain significance (May 27, 2022)3337141
19-18868641-G-A Uncertain significance (Oct 13, 2022)660810
19-18868650-C-T Uncertain significance (Jan 05, 2024)3367614
19-18868664-T-TCAAAGAAGAGCA Uncertain significance (May 11, 2020)998691
19-18868665-CAAAG-C Congenital heart defects, multiple types, 6 Pathogenic/Likely pathogenic (Jan 25, 2023)410641
19-18868666-AAAG-A Visceral heterotaxy • Progressive myoclonic epilepsy type 8 Uncertain significance (Aug 31, 2021)471935
19-18868673-A-G Uncertain significance (Jul 28, 2023)2737779
19-18868675-C-A GDF1-related disorder Likely benign (May 29, 2022)1085392
19-18868678-G-A Likely benign (Apr 02, 2018)705539
19-18868681-G-A Likely benign (Feb 23, 2023)2899255
19-18868686-G-A Uncertain significance (Sep 01, 2021)659753
19-18868687-C-T Progressive myoclonic epilepsy type 8 Likely benign (Jul 10, 2018)705802
19-18868688-G-C Uncertain significance (Aug 08, 2019)959657
19-18868697-G-C Uncertain significance (Dec 03, 2020)1512258
19-18868700-G-A not specified Uncertain significance (Aug 08, 2022)2305894
19-18868700-G-T Uncertain significance (Dec 05, 2020)1380829
19-18868708-G-C - no classification for the single variant (-)2663905

GnomAD

Source: gnomAD

GeneTypeBio TypeTranscript Coding Exons Length
CERS1protein_codingprotein_codingENST00000427170 728176
pLI Probability
LOF Intolerant
pRec Probability
LOF Recessive
Individuals with
no LOFs
Individuals with
Homozygous LOFs
Individuals with
Heterozygous LOFs
Defined p
0.09660.896123555071235620.0000283
Z-Score Observed Expected Observed/Expected Mutation Rate Total Possible in Transcript
Missense0.8151371670.8220.00001072206
Missense in Polyphen3956.450.69088656
Synonymous-0.1877573.01.030.00000507702
Loss of Function2.35413.20.3025.64e-7172

LoF frequencies by population

EthnicitySum of pLOFs p
African & African-American0.000.00
Ashkenazi Jewish0.000.00
East Asian0.0001150.000111
Finnish0.000.00
European (Non-Finnish)0.00004560.0000451
Middle Eastern0.0001150.000111
South Asian0.000.00
Other0.000.00

dbNSFP

Source: dbNSFP

Function
FUNCTION: May be either a bona fide (dihydro)ceramide synthase or a modulator of its activity. When overexpressed in cells is involved in the production of sphingolipids containing mainly one fatty acid donor (N-linked stearoyl- (C18) ceramide) in a fumonisin B1-independent manner (By similarity). {ECO:0000250|UniProtKB:P27545}.;
Disease
DISEASE: Epilepsy, progressive myoclonic 8 (EPM8) [MIM:616230]: A severe form of progressive myoclonic epilepsy characterized by myoclonus, generalized tonic-clonic seizures and moderate to severe cognitive impairment. {ECO:0000269|PubMed:24782409}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
Pathway
Sphingolipid signaling pathway - Homo sapiens (human);Sphingolipid metabolism - Homo sapiens (human);Developmental Biology;Metabolism of lipids;Metabolism;Signaling by NODAL;ceramide <i>de novo</i> biosynthesis;Sphingolipid de novo biosynthesis;Sphingolipid metabolism (Consensus)

Intolerance Scores

loftool
rvis_EVS
-0.67
rvis_percentile_EVS
15.62

Haploinsufficiency Scores

pHI
hipred
N
hipred_score
0.318
ghis
0.569

Essentials

essential_gene_CRISPR
N
essential_gene_CRISPR2
N
essential_gene_gene_trap
N
gene_indispensability_pred
N
gene_indispensability_score
0.114

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumMedium
CancerMediumMediumMedium

Mouse Genome Informatics

Gene name
Cers1
Phenotype
growth/size/body region phenotype; cellular phenotype; homeostasis/metabolism phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); pigmentation phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan);

Gene ontology

Biological process
sphingolipid biosynthetic process;cellular response to drug;cellular response to mycotoxin;ceramide biosynthetic process;negative regulation of telomerase activity;cellular response to UV-A;cellular response to dithiothreitol
Cellular component
Golgi membrane;endoplasmic reticulum;endoplasmic reticulum membrane;membrane;integral component of membrane;intracellular membrane-bounded organelle
Molecular function
molecular_function;sphingosine N-acyltransferase activity